NASDAQ: ARCTArcturus Therapeutics Holdings Inc Stock
$7.35+0.07 (+0.96%)
Updated Jul 6, 2026
ARCT Price
$7.35
Fair Value Price
-$5.78
Market Cap
$208.91M
52 Week Low
$5.85
52 Week High
$24.17
P/E
-2.6x
P/B
1.09x
P/S
4.01x
PEG
N/A
Dividend Yield
N/A
Revenue
$54.71M
Earnings
-$78.67M
Gross Margin
100%
Operating Margin
-143.8%
Profit Margin
-143.8%
Debt to Equity
0.28
Operating Cash Flow
-$59M
Beta
1.99
Next Earnings
Aug 10, 2026
Ex-Dividend
N/A
Next Dividend
N/A
ARCT Overview
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ARCT's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -12.86% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important ARCT news, forecast changes, insider trades & much more!
ARCT News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ARCT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ARCT ($7.35) is overvalued by 227.11% relative to our estimate of its Fair Value price of -$5.78 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ARCT ($7.35) is not significantly undervalued (227.11%) relative to our estimate of its Fair Value price of -$5.78 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ARCT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ARCT due diligence checks available for Premium users.
Valuation
ARCT fair value
Fair Value of ARCT stock based on Discounted Cash Flow (DCF)
Price
$7.35
Fair Value
-$5.78
Undervalued by
227.11%
ARCT ($7.35) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ARCT ($7.35) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ARCT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ARCT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.6x
Industry
18.36x
Market
6.94x
ARCT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.09x
Industry
5.58x
ARCT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ARCT's financial health
Profit margin
Revenue
$2.1M
Net Income
-$27.0M
Profit Margin
-1,308.3%
ARCT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ARCT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$245.4M
Liabilities
$54.0M
Debt to equity
0.28
ARCT's short-term assets ($216.88M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ARCT's short-term assets ($216.88M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ARCT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ARCT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$19.4M
Investing
$34.0k
Financing
$16.0k
ARCT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ARCT vs Biotech Stocks
Arcturus Therapeutics Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.